retatrutide drug trial Results: 28.3% Weight Loss Data Eli Lilly and Company's Retatrutide

Clinical trials suggest GLP-1 medications are safe for diverse patient populations

Antioxidants 11 , 306 (2022)

Additionally, some patients unconsciously increase calorie intake as nausea decreases or adapt to side effects, offsetting the medication's metabolic benefits

The effect of this study could have profound significance as it could lead to improved quality of life for the individual as well as societal improvement if academic and work-related productivity can be improved

Development of New and Improved Formulations is Bolstering the GLP-1 Analogues Market Share Novel and advanced drug formulation technologies are amongst the key drivers in the GLP-1 analogues market

Published 2023